Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Cassava Sciences's interest expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Cassava Sciences's Operating Income for the
three
months ended in Dec. 2023 was $ -22.79 Mil. Cassava Sciences's Interest Expense for the
three
months ended in Dec. 2023 was $ 0.00 Mil.
Cassava Sciences has no long-term debt (1).
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Cassava Sciences Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cassava Sciences (NAS:SAVA) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Cassava Sciences's Interest Expense for the
three
months ended in Dec. 2023 was $0.00 Mil. Its
Operating Income
for the
three
months ended in Dec. 2023 was $-22.79 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Dec. 2023 was $0.00 Mil.
Cassava Sciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as
| Cassava Sciences had no long-term debt (1). |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Good Sign:
Cassava Sciences Inc has no debt.
Cassava Sciences (Cassava Sciences) Business Description
Traded in Other Exchanges
Address
6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms.
Executives
| Sanford Robertson |
director |
ONE LETTERMAN DRIVE, BUILDING C SUITE 410, SAN FRANCISCO CA 94129 |
| Richard Barry |
director |
285 MARGALITA DRIVE, SAN RAFAEL CA 94901 |
| Robert Christopher Cook |
officer: SVP & General Counsel |
6801 N. CAPITAL OF TEXAS HWY, BUILDING 1, SUITE 300, AUSTIN TX 78731 |
| James William Kupiec |
officer: Chief Clinical Dev. Officer |
7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN TX 78731 |
| Eric Schoen |
officer: Chief Financial Officer |
7801 N. CAPITAL OF TX HWY, SUITE 260, AUSTIN TX 78731 |
| Remi Barbier |
director, 10 percent owner, officer: CEO, Chairman of the Board |
|
| Armistice Capital Master Fund Ltd. |
10 percent owner |
C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
| Armistice Capital, Llc |
10 percent owner |
510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
| Steven Boyd |
10 percent owner |
510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022 |
| O Donnell Michael J |
director |
|
| Robert Z Gussin |
director |
|
| Scannon Patrick J Md Phd |
director |
C/O XOMA, LTD., 2910 SEVENTH STREET, BERKELEY CA 94710 |
| Saira Ramasastry |
director |
501 CANAL BLVD., RICHMOND CA 94804 |
| Nadav Friedmann |
director, officer: Chief Scientific Officer |
|
| Sabretooth Master Fund, L.p. |
10 percent owner |
405 LEXINGTON AVENUE, 50TH FLOOR, NEW YORK NY 10174 |
Cassava Sciences (Cassava Sciences) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
SAVA has been successfully added to your 